Point72 Hong Kong’s Keros Therapeutics KROS Stock Holding History

Point72 Hong Kong’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,006	Closed	-$28K	–	2179
2022 Q2	$28K	Buy	+1,006	New	+$44.1K	﹤0.01%	1488
2022 Q1	–	Sell	-198	Closed	-$12K	–	2103
2021 Q4	$12K	Buy	+198	New	+$9.87K	﹤0.01%	1614

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Hong Kong's KROS Position: Q3 2022 in Review

Point72 Hong Kong sold out of Keros Therapeutics (KROS) in Q3 2022, closing a stake of 1,006 shares — an estimated $28K sold.

Point72 Hong Kong first reported a position in KROS in Q4 2021 and held it in 2 quarters. The position peaked at $28K in Q2 2022. 113 funds tracked by Wall St. Rank hold KROS as of Q3 2022.

Point72 Hong Kong reported no remaining Keros Therapeutics position as of Q3 2022 after selling out during the quarter.
Point72 Hong Kong sold 1,006 Keros Therapeutics shares in Q3 2022, an estimated $28K.
Point72 Hong Kong first reported a position in Keros Therapeutics in Q4 2021 and held it in 2 quarters.
Point72 Hong Kong's Keros Therapeutics position peaked at $28K in Q2 2022.
113 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.